Previous studies have shown that TCF7L2 is highly expressed in hepatocellular carcinoma, breast cancer, esophageal squamous cell carcinoma, and other malignant tumors, and its expression correlates with their progress [9–13]. This evidence concerns the gene TCF7L2 and breast cancer.